IPHYF OTC
Innate Pharma S.A.
1W: -8.5%
1M: -8.5%
3M: -8.5%
YTD: -29.8%
1Y: -24.5%
3Y: -44.3%
5Y: -65.8%
$1.51
-0.14 (-8.53%)
Weekly Expected Move ±4.2%
$1
$1
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$63M
-43.5% ▼
5Y CAGR: -27.2%
Total Liabilities
$84M
-17.4% ▼
5Y CAGR: -11.0%
Shareholders Equity
-$22M
-345.6% ▼
Cash & Investments
$34M
-57.5% ▼
5Y CAGR: -25.7%
Total Debt
$23M
-27.2% ▼
5Y CAGR: +3.4%
Net Debt
-$6M
+84.4% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $104M | $84M | $71M | $66M | $28M |
| Short-Term Investments | $16M | $17M | $22M | $14M | $6M |
| Cash & ST Investments | $120M | $101M | $92M | $81M | $34M |
| Net Receivables | $846K | $3M | $46M | $2M | $12M |
| Inventory | $0 | -$2K | $0 | $0 | $0 |
| Other Current Assets | $13M | $31M | $0 | $0 | $0 |
| Total Current Assets | $138M | $140M | $148M | $86M | $47M |
| Property, Plant & Equip. | $10M | $9M | $6M | $5M | $4M |
| Goodwill & Intangibles | $44M | $2M | $416K | $0 | $0 |
| Long-Term Investments | $40M | $35M | $10M | $10M | $11M |
| Other Non-Current Assets | $30M | $14M | $2M | $10M | $947K |
| Total Non-Current Assets | $129M | $68M | $27M | $25M | $16M |
| Total Assets | $267M | $208M | $175M | $111M | $63M |
| — Liabilities — | |||||
| Accounts Payable | $15M | $14M | $9M | $8M | $15M |
| Short-Term Debt | $30M | $1M | $8M | $8M | $9M |
| Deferred Revenue | $12M | $7M | $6M | $616K | $3M |
| Other Current Liabilities | $22M | $19M | $8M | $8M | $10M |
| Total Current Liabilities | $80M | $41M | $40M | $33M | $37M |
| Long-Term Debt | $11M | $39M | $31M | $22M | $14M |
| Other Non-Current Liab. | $36M | $56M | $39M | $44M | $34M |
| Total Non-Current Liabilities | $80M | $112M | $84M | $69M | $48M |
| Total Liabilities | $160M | $154M | $132M | $102M | $84M |
| — Equity — | |||||
| Common Stock | $4M | $4M | $4M | $4M | $5M |
| Retained Earnings | -$272M | -$330M | -$337M | -$386M | -$435M |
| Accumulated OCI | $456K | $819K | $495K | $27K | $0 |
| Total Stockholders Equity | $107M | $54M | $52M | $9M | -$22M |
| Total Liabilities & Equity | $267M | $208M | $184M | $111M | $63M |
| — Key Metrics — | |||||
| Total Debt | $44M | $42M | $40M | $31M | $23M |
| Net Debt | -$60M | -$42M | -$31M | -$35M | -$6M |
| Total Investments | $56M | $52M | $32M | $25M | $17M |